Sanibel Captiva Trust Company Inc. Sells 2,167 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Sanibel Captiva Trust Company Inc. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 39.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,389 shares of the medical research company’s stock after selling 2,167 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Charles River Laboratories International were worth $510,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of CRL. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Charles River Laboratories International by 46.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company’s stock worth $987,000 after purchasing an additional 1,679 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in Charles River Laboratories International by 11.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 125,097 shares of the medical research company’s stock valued at $23,093,000 after buying an additional 13,102 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Charles River Laboratories International by 2.3% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 5,951 shares of the medical research company’s stock valued at $1,099,000 after buying an additional 133 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after buying an additional 47,221 shares during the last quarter. Finally, Asset Management One Co. Ltd. increased its position in shares of Charles River Laboratories International by 1.7% during the 4th quarter. Asset Management One Co. Ltd. now owns 18,918 shares of the medical research company’s stock valued at $3,522,000 after purchasing an additional 315 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business’s stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president now directly owns 19,513 shares of the company’s stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

CRL opened at $151.02 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The stock has a market capitalization of $7.42 billion, a PE ratio of 1,006.82, a price-to-earnings-growth ratio of 4.54 and a beta of 1.48. The stock’s 50 day moving average price is $128.17 and its 200-day moving average price is $158.06.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period in the previous year, the company posted $2.27 earnings per share. The firm’s revenue was down 2.7% on a year-over-year basis. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CRL shares. Robert W. Baird raised their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a “neutral” rating in a research report on Thursday, May 8th. TD Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 price objective for the company in a report on Wednesday, May 14th. Evercore ISI raised shares of Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 price objective for the company in a research note on Thursday, May 8th. Cowen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Wednesday, May 14th. Finally, Barclays raised their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the company an “equal weight” rating in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $171.85.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).